MedeliX
Start asking

secukinumab

Cosentyx · ATC code L04AC10

Key facts
Active substance
secukinumab
Drug class
Immunosuppressive drug
ATC code
L04AC10
Authorisation
centrally authorised across the EU (EMA)
Dosage forms
Cosentyx 75 mg solution for injection in pre-filled syringe · Cosentyx 150 mg solution for injection in pre-filled syringe / Cosentyx 300 mg solution for injection in pre-filled syringe / Cosentyx 150 mg solution for injection in pre-filled pen · Cosentyx 150 mg powder for solution for injection
Marketing authorisation holder
Novartis Europharm Limited
Information as of
2026-10-27

Key facts

Secukinumab (Cosentyx) is an interleukin-17A-directed monoclonal antibody for plaque psoriasis, psoriatic arthritis, axial spondyloarthritis, hidradenitis suppurativa and juvenile idiopathic arthritis.

What it is used for

  • Moderate to severe plaque psoriasis in adults and in children and adolescents from 6 years
  • Psoriatic arthritis, ankylosing spondylitis and non-radiographic axial spondyloarthritis in adults
  • Hidradenitis suppurativa in adults
  • Enthesitis-related arthritis and juvenile psoriatic arthritis from 6 years, alone or with methotrexate

Dosing

  • Adult plaque psoriasis: 300 mg subcutaneously at weeks 0, 1, 2, 3 and 4, then monthly; 300 mg every 2 weeks may help patients of 90 kg or higher
  • Hidradenitis suppurativa: 300 mg on the same schedule; maintenance may be increased to every 2 weeks
  • Psoriatic arthritis: 300 mg in anti-TNFα inadequate responders, otherwise 150 mg (can be increased to 300 mg)
  • Axial spondyloarthritis: 150 mg at weeks 0 to 4, then monthly; in ankylosing spondylitis can be increased to 300 mg
  • Children: weight-based dose (75 mg or 150 mg; tables in full text)
  • Consider discontinuation if no response by 16 weeks

Contraindications

  • Hypersensitivity to the active substance or any excipient
  • Clinically important active infection (e.g. active tuberculosis)

Important warnings

  • Increased risk of infections, including serious infections; do not administer until a serious infection resolves
  • Evaluate for tuberculosis before starting
  • New or worsening inflammatory bowel disease; not recommended in IBD
  • Rare anaphylaxis and angioedema; the 75 mg syringe needle cap contains a latex derivative

Side effects

  • Most frequent: upper respiratory tract infections (mostly nasopharyngitis, rhinitis)
  • Other adverse reactions by frequency in the table in the full text

Interactions

  • Live vaccines should not be given concurrently
  • No interaction observed with midazolam, methotrexate or corticosteroids

Pregnancy and breastfeeding

  • Effective contraception during and for at least 20 weeks after treatment; preferable to avoid use in pregnancy

Summary of the official product information, written with AI (Claude, Anthropic) on 2026-10-28. Every number was checked automatically against the original text. Not reviewed by a physician – the full official text is authoritative.

Full official text →

Common questions – ask Medelix

For patients

Package leaflet, verbatim

Package leaflet for patients →

Authorisation and brand names by country

Medicines with exactly this active-substance composition, as listed in the national registers – alphabetical and without ranking. Whether a product is currently available is not shown here.

EU – centrally authorised (all member states)

  • CosentyxNovartis Europharm Limited · EMEA/H/C/003729

Source: European Medicines Agency (EMA), product information

Turkey

  • VerxantFARMANOVA SAĞLIK HİZMETLERİ LTD. ŞTİ. · 3 register entries

Source: TİTCK – Ruhsatlı Beşeri Tıbbi Ürünler Listesi, as of 2026-10-16

Brand names in 3 more European countries
Iceland
Cosentyx
Liechtenstein
Cosentyx
Norway
Cosentyx

EMA – Article 57 product data (EU/EEA), 2026-10-28

Medelix receives no money from pharmaceutical companies. Brand names are listed alphabetically and without ranking.

Other substances in the same group

Another question about this substance?

Medelix answers clinical questions from guidelines, studies and product information – every claim with its source.

Sources

  1. European Medicines Agency. Cosentyx – EPAR, Product Information (OF THE TEXT Detailed information on this medicinal product i). 2026-10-27. https://www.ema.europa.eu/en/documents/product-information/cosentyx-epar-product-information_en.pdf
  2. TİTCK – Ruhsatlı Beşeri Tıbbi Ürünler Listesi, 2026-10-16. https://www.titck.gov.tr/dinamikmodul/85
  3. Wikidata (CC0): ATC L04AC.

Editorial: Medelix editorial team · last updated 2026-10-27 · How these pages are made · Report an error

Source: European Medicines Agency (EMA), product information. Not advertising, not a treatment recommendation. For questions about your own treatment, ask your doctor or pharmacist.